Replimune Group Faces Securities Class Action Investigation
ByAinvest
Friday, Aug 15, 2025 10:22 am ET1min read
REPL--
The investigation is focused on allegations that Replimune and its executives made false and/or misleading statements and/or failed to disclose material issues. Specifically, the firm is examining claims that Replimune recklessly overstated the prospects of its IGNYTE trial, which resulted in the FDA deeming the trial inadequate and not well-controlled. This, in turn, led to materially false and misleading statements about Replimune's business, operations, and prospects.
On July 22, 2025, Replimune issued a press release stating that it had received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1. The CRL indicated that the FDA was unable to approve the application in its present form due to the IGNYTE trial's inadequacy. This announcement led to a significant drop in Replimune's common stock, plummeting over 73% during intraday trading.
Investors who wish to discuss their legal rights should contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The deadline to seek lead plaintiff status in a federal securities class action that has been filed against the company is September 22, 2025.
References:
[1] https://www.morningstar.com/news/globe-newswire/9510411/shareholder-action-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-replimune
[2] https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-22-2025-in-replimune-group-inc-lawsuit--repl-302530663.html
[3] https://www.morningstar.com/news/pr-newswire/20250809ny47607/faruqi-faruqi-reminds-replimune-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025-repl
Faruqi & Faruqi is investigating potential claims against Replimune Group, a biotechnology company. The firm is looking into allegations of securities fraud related to the company's financial statements between November 2024 and July 2025. Investors who suffered losses during this period may contact Faruqi & Faruqi partner Josh Wilson to discuss their options. The deadline to seek lead plaintiff status is September 22, 2025.
New York, Aug. 9, 2025 — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company. The firm is looking into allegations of securities fraud related to the company's financial statements between November 2024 and July 2025. Investors who suffered losses during this period are encouraged to contact Faruqi & Faruqi partner Josh Wilson to discuss their options.The investigation is focused on allegations that Replimune and its executives made false and/or misleading statements and/or failed to disclose material issues. Specifically, the firm is examining claims that Replimune recklessly overstated the prospects of its IGNYTE trial, which resulted in the FDA deeming the trial inadequate and not well-controlled. This, in turn, led to materially false and misleading statements about Replimune's business, operations, and prospects.
On July 22, 2025, Replimune issued a press release stating that it had received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1. The CRL indicated that the FDA was unable to approve the application in its present form due to the IGNYTE trial's inadequacy. This announcement led to a significant drop in Replimune's common stock, plummeting over 73% during intraday trading.
Investors who wish to discuss their legal rights should contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The deadline to seek lead plaintiff status in a federal securities class action that has been filed against the company is September 22, 2025.
References:
[1] https://www.morningstar.com/news/globe-newswire/9510411/shareholder-action-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-replimune
[2] https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-22-2025-in-replimune-group-inc-lawsuit--repl-302530663.html
[3] https://www.morningstar.com/news/pr-newswire/20250809ny47607/faruqi-faruqi-reminds-replimune-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025-repl
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet